Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katherine Boggs

Physician Assistant, Medical South Charleston, WV Physician Assistant

NPI 1295170587 CMS profile 194311

4619 Kanawha Avenue Sw, South Charleston, WV 25309

Open in the dashboard

General payments

$46,261

440 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Boggs of South Charleston, WV is reported in the CMS Open Payments database as having received $46,261 across 440 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,415 77
2024 General $13,104 96
2023 General $8,651 80
2022 General $6,151 87
2021 General $3,939 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Boggs
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Katherine Boggs were reported at $14,415. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Katherine Boggs Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,939 $156 $41–$563 $132
2022 $6,151 $185 $55–$649 $149
2023 $8,651 $199 $58–$717 $160
2024 $13,104 $206 $62–$740 $164
2025 $14,415 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Johnson & Johnson Health Care Systems Inc. $19,679 38 payments
  2. Actelion Pharmaceuticals US, Inc. $17,896 67 payments
  3. Regeneron Healthcare Solutions, Inc. $1,486 29 payments
  4. AstraZeneca Pharmaceuticals LP $1,172 46 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,096 47 payments
  6. United Therapeutics Corporation $1,004 10 payments
  7. GlaxoSmithKline, LLC. $788 51 payments
  8. Genzyme Corporation $622 28 payments
  9. Axsome Therapeutics, Inc. $338 14 payments
  10. Amgen Inc. $263 15 payments
  11. Other $1,916 95 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $14,556 16 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,855 13 payments
  3. Food and Beverage $9,177 374 payments
  4. Travel and Lodging $8,230 31 payments
  5. Education $442 6 payments
Products named General payments · program years 2021–2025
  1. UPTRAVI $33,634 98 payments
  2. OPSUMIT $33,261 78 payments
  3. VELETRI $16,938 34 payments
  4. DUPIXENT Inflammation And Immunology $1,333 24 payments
  5. OFEV $1,127 49 payments
  6. TYVASO $904 9 payments
  7. FASENRA $767 18 payments
  8. DUPIXENT Immunology $702 29 payments
  9. BREZTRI $685 21 payments
  10. TRELEGY ELLIPTA $415 27 payments
  11. Other $3,889 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

705

Median for Physician Assistant: 241

Drug cost

$280,777

Median for Physician Assistant: $4,110

Branded share of claims

63%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 87 $102,200
Dupixent Pen Dupilumab Brand 16 $61,433
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 23 $21,995
Breo Ellipta Fluticasone/Vilanterol Brand 34 $21,740
Symbicort Budesonide/Formoterol Fumarate Brand 49 $21,166
Spiriva Respimat Tiotropium Bromide Brand 26 $16,349
Spiriva Handihaler Tiotropium Bromide Brand 14 $9,000
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 30 $7,324
Albuterol Sulfate Hfa Albuterol Sulfate Brand 119 $6,239
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 22 $5,441

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$9,544

Medicare's payments for the services billed

Medicare patients

154

Average age 74

Services billed

166

89 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 68%
Arthritis 68%
Ischemic heart disease 62%
Diabetes 48%
Chronic kidney disease 44%
Atrial fibrillation 37%
Heart failure 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $2,912
  • Johnson & Johnson Health Care Systems Inc. $1,978
$4,890 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $2,912
  • Johnson & Johnson Health Care Systems Inc. $1,978
$4,890 — —
VELETRI
  • Johnson & Johnson Health Care Systems Inc. $1,978
$1,978 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $181
$181 — —
DUPIXENT
  • GENZYME CORPORATION $106
  • Regeneron Healthcare Solutions, Inc. $72
$178 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

440 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record